Format

Send to

Choose Destination
Nutr Cancer. 2012;64(5):749-60. doi: 10.1080/01635581.2012.689413. Epub 2012 Jun 4.

Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer.

Author information

1
Department of Nutrition, University of Tennessee, Knoxville, Tennessee 37996-192, USA.

Abstract

Prostate cancer (PrC) is the second deadliest cancer of males in the United States Hormone deprivation therapy (HDT), a common therapy for advanced forms of the disease, results in tumor regression; unfortunately, tumors inevitably become castrate-resistant. Diet is not an appropriate primary therapy for refractory forms of the disease; however, diet may be effective as an adjuvant to HDT, potentially extending the latency period and delaying relapse and/or inhibiting refractory growth. Zyflamend® is a combination of extracts from multiple herbs, each with reported anticancer properties. Zyflamend can inhibit growth of various PrC cell lines, but no studies have investigated its potential use in vivo using a model of castrate-resistant PrC. In this study, oral doses of Zyflamend at human equivalent doses inhibited androgen-dependent and castrate-resistant tumor growth in a mouse model that mimics advanced stages of the disease, and reduced the expression of a number of biomarkers linked to PrC progression including pAKT, prostate specific antigen, histone deacetylases, and androgen receptor. In summary, this is the first article to report that Zyflamend, when provided at human equivalent doses, can potentiate the effects of hormone deprivation on tumor regression and growth inhibition of androgen-dependent and castrate-resistant PrC tumors in vivo.

PMID:
22663543
DOI:
10.1080/01635581.2012.689413
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center